Skip to main content
TipRanks
Go Ultimate75% OFF

Becton Dickinson (BDX) AI Stock Analysis

2,154 Followers
BDX

Becton Dickinson

(NYSE:BDX)

Select Model
Rating:65Neutral
Price Target:$225.00â–²(4.45% Upside)
Action:reiterated
Date:11/05/26

BDX scores as a mid-range opportunity driven primarily by steady fundamentals and strong cash generation, supported by a positive earnings call highlighting share gains, productivity, and improving free cash flow. The score is held back by near-term profitability/ROE pressure and a very high P/E, while technicals are positive but look overextended (high RSI/Stochastics), increasing near-term pullback risk.

Positive Factors
Recurring consumables and workflow integrationBD's recurring consumables and embedded clinical workflows can support repeat purchasing across hospitals, laboratories, and pharmaceutical customers. Standardization and switching costs reinforce customer retention, while instrument-linked reagents and services broaden the recurring revenue base over the next several quarters.
Negative Factors
Weak recent revenue and profitabilityRecent revenue contraction and weaker net-margin conversion indicate that stable gross and EBITDA margins have not fully translated into bottom-line performance. Lower ROE also signals reduced earnings power relative to the equity base, limiting near-term returns from the business.

Becton Dickinson Key Performance Indicators (KPIs)

Revenue by GeographyShows how Becton Dickinson’s sales are split across regions (U.S., Europe, Asia, etc.), revealing where revenue and growth are concentrated, which markets expose the company to regulatory or reimbursement risks, and how sensitive results are to currency swings.

$0.00$500.00M$1.00B$1.50B$2.00B$2.50BMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26
Chart Insights

International revenue showed sustained recovery through 2023–25 driven by biologics and other growth platforms, but the sharp drop in the most recent quarter likely reflects China market softness and the temporary shipment hold tied to an FDA warning letter, reversing momentum. Management’s guidance assumes H2 roughly similar to H1 and a modest FX tailwind, but near‑term China and logistics risks make international results the primary downside threat to meeting low-single-digit full‑year growth and margin targets.

Data provided by:The Fly

Becton Dickinson (BDX) vs. SPDR S&P 500 ETF (SPY)

-10%0%10%20%30%40%50%60%BDX+48.21%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$58.68B
Dividend Yield
1.85%
Average Volume (3M)
1.82M
Price to Earnings (P/E)
52.0
Beta (1Y)
0.32
Revenue Growth
-7.40%
EPS Growth
-28.89%
Country
US
Employees
60,000
Sector
Healthcare
Sector Strength
51
Industry
Medical - Instruments & Supplies

Becton Dickinson Business Overview & Revenue Model

Company Description

Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, a...

How the Company Makes Money

BD primarily makes money by selling medical devices and consumable supplies to hospitals, clinics, laboratories, life science researchers, and pharmaceutical companies. A significant portion of revenue comes from recurring, high-volume consumables (f...

Becton Dickinson Earnings Call Summary

Earnings Call Date:Nov 05, 2026(Q4-2026)|% Change Since:2.98%|Next Earnings Date:Feb 04, 2027
Earnings Call SentimentPositive

The call was strongly positive, supported by strong Q4 revenue and adjusted EPS growth, broad-based momentum across key platforms, share gains, improved cash flow, productivity gains, innovation progress, and a completed portfolio transformation. The main challenges were the Alaris comparison, low-single-digit fiscal 2027 revenue guidance, flat reported operating margins, inflation and tariff effects, and the Q4 vaccine decline, but management characterized several of these pressures as temporary or moderating and expressed confidence in continued growth and margin expansion beyond fiscal 2027.

Positive Updates

Strong Fourth-Quarter and Full-Year Results
Q4 revenue was $5.3 billion, up 5.6%, and adjusted EPS was $4.15, up 27.3%. Full-year revenue was $19.5 billion, up 3.9%, and adjusted EPS was $12.70, up 6.7%.

Negative Updates

Fiscal 2027 Revenue Guidance Moderates
BD expects fiscal 2027 full-year revenue growth in the low single digits. At the midpoint, growth excluding the Alaris capital comparison is expected to be mid-single digit, while currency is expected to be a headwind of about 70 basis points.

Company Guidance

For fiscal 2027, BD expects low single-digit growth for the full year, with currency estimated to be a headwind of about 70 basis points and an approximate 200 basis points impact from the Alaris capital comparison; excluding this impact, BD expects mid-single-digit growth at the midpoint of its guidance. Adjusted operating margins are expected to be roughly flat year-over-year, the adjusted tax rate is expected to be between 16% and 17%, weighted average shares outstanding are expected to be approximately 273 million, and adjusted EPS is expected to be in a range of $13.10 to $13.30. Q1 revenue growth is expected to be at the low end of the range, the first half is expected to be in line with the midpoint of the full year guidance, and Q1 adjusted EPS is expected to be between $2.32 and $2.37, with earnings growth expected to accelerate in Q2 and the second half of the year.

Becton Dickinson Financial Statement Overview

Summary

Financials are steady but not accelerating. Cash flow is a clear strength (positive and growing TTM free cash flow, +7.79%), and leverage looks manageable with improving TTM debt-to-equity. Offsetting this, the income statement shows near-term pressure with TTM revenue down (-2.96%), net margin falling to ~4.5%, and ROE down to ~3.8%, signaling weaker profitability and returns despite stable gross/EBITDA margins.

Income Statement

62Positive

Balance Sheet

68Positive

Cash Flow

71Positive
Financial statement breakdown
BreakdownTTMSep 2026Sep 2025Sep 2024Sep 2023Sep 2022
Income Statement
Total Revenue20.22B19.46B21.84B20.18B19.37B18.87B
Gross Profit9.57B9.21B9.92B9.13B8.17B8.48B
EBITDA4.69B4.61B4.96B4.82B4.40B4.41B
Net Income1.14B1.15B1.68B1.71B1.48B1.78B
Balance Sheet
Total Assets50.79B50.79B55.33B57.29B52.78B52.93B
Cash, Cash Equivalents and Short-Term Investments733.00M733.00M859.00M2.30B1.42B1.17B
Total Debt16.34B16.34B19.18B21.59B16.82B16.95B
Total Liabilities26.11B26.11B29.94B31.40B26.98B27.65B
Stockholders Equity24.68B24.68B25.39B25.89B25.80B25.28B
Cash Flow
Free Cash Flow2.77B2.69B2.67B3.07B2.12B1.66B
Operating Cash Flow3.44B3.37B3.43B3.80B2.99B2.63B
Investing Cash Flow-994.00M-1.05B-818.00M-5.51B-716.00M-3.23B
Financing Cash Flow-2.24B-2.16B-3.62B2.09B-1.96B-591.00M

Becton Dickinson Technical Analysis

Technical Analysis SentimentPositive
Last Price215.42

Price Trends

50DMA192.29Positive
100DMA180.88Positive
200DMA167.73Positive

Market Momentum

MACD7.40Negative
RSI69.74Neutral
STOCH79.18Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BDX, the sentiment is Positive. The current price of 215.42 is above the 20-day moving average (MA) of 205.79, above the 50-day MA of 192.29, and above the 200-day MA of 167.73, indicating a bullish trend. The MACD of 7.40 indicates Negative momentum. The RSI at 69.74 is Neutral, neither overbought nor oversold. The STOCH value of 79.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BDX.

Becton Dickinson Risk Analysis

Becton Dickinson disclosed 25 risk factors in its most recent earnings report. Becton Dickinson reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.We may not realize some or all of the expected benefits of the combination of our Biosciences and Diagnostic Solutions business with Waters.Q3, 2025
2.The proposed combination of our Biosciences and Diagnostic Solutions business with Waters may not be completed, on the currently contemplated timeline or at all.Q3, 2025
3.The announcement and pendency of the combination of our Biosciences and Diagnostic Solutions business with Waters could cause disruptions in our business.Q3, 2025

Becton Dickinson Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

BDX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
WSTWST78Outperform$28.85B46.1521.08%0.22%12.60%32.05%
MDLNMDLN65Neutral$49.57B56.524.97%―11.85%-57.19%
BDXBDX65Neutral$58.68B52.054.64%1.85%-7.40%-28.89%
ICUIICUI64Neutral$4.42B74.272.81%―-5.82%―
BAXBAX58Neutral$13.33B-18.63-11.62%0.16%5.33%-164.67%
TFXTFX57Neutral$6.33B19.249.74%0.85%-29.30%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-20%0%20%40%60%BDXBAXICUITFXWSTMDLNDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
BDX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
BDXBecton, Dickinson and Co215.4268.8146.94%
BAXBaxter International Inc25.768.1145.91%
ICUIICU Medical176.9144.3433.45%
TFXTeleflex159.5554.9252.49%
WSTWest Pharmaceutical Services, Inc.414.12156.9861.05%
MDLNMedline, Inc. Class A37.68-3.32-8.10%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 05, 2026